SCHEMBL5563407

SCHEMBL5563407

CCCOc1cc(NC(=O)OC(C)(C)C)c([N+](=O)[O-])cc1C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP2C9 P11712 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
LMNA P02545 3/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 2/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
AR P10275 5/20 0.38
CYP3A4 P08684 2/20 0.38
PGR P06401 1/20 0.38
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
AKR1C1 Q04828 1/20 0.37
CYP19A1 P11511 1/20 0.37
AAK1 Q2M2I8 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5563185 0.91 CYP3A4 (0.44) SMN1; SMN2CYP1A2NPC1RAB9ALMNA
SCHEMBL5563828 0.91 HTT (0.40) SMN1; SMN2CYP1A2LMNAPOLBMAPT
SCHEMBL5563504 0.89 AAK1 (0.41) ARAAK1
SCHEMBL27597130 0.87 CYP1A2 (0.45) SMN1; SMN2CYP1A2CYP2C9NPC1RAB9A
SCHEMBL5563248 0.85 LMNA (0.42) SMN1; SMN2CYP1A2CYP2C9LMNAPOLB
SCHEMBL5557898 0.85 HTR2A (0.37) LMNAPOLBMAPTMAPK1AR
SCHEMBL5564095 0.82 AAK1 (0.40) LMNAPOLBMAPTAAK1
SCHEMBL5556419 0.81 LMNA (0.43) SMN1; SMN2CYP1A2CYP2C9RAB9ALMNA
SCHEMBL5557383 0.81 LMNA (0.43) SMN1; SMN2CYP1A2CYP2C9LMNAPOLB
SCHEMBL5557362 0.80 LMNA (0.41) SMN1; SMN2CYP1A2CYP2C9LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474416-B1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS HOFFMANN LA ROCHE (CH) 2007-09-26 EP disclosed
US-6949542-B2 Dihydro-benzo[b][1,4]diazepin-2-one derivatives HOFFMAN-LA ROCHE INC. (US) 2005-09-27 US disclosed
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG (CH) 2003-09-04 US disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives CYP1B1, GRIN2B, CYP4B1 SMN1; SMN2 538/4885CYP1A2 34/4885CYP2C9 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.